A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.
暂无分享,去创建一个
M. Climent | E. Esteban | A. Font | I. Durán | D. Castellano | P. Maroto | J. Puente | T. Alonso-Gordoa | M. Lázaro-Quintela | M. Sáez | M. J. Juan Fita | B. Pérez-Valderrama | C. Santander Lobera | A. González-del-Alba | A. Sánchez-Hernandez | C. Garcías | María José Méndez-Vidal | Jóse Ángel Arranz Arija | B. Mellado Gonzalez | Javier Cassinello-Espinosa
[1] J. Carles,et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design , 2022, The Lancet.
[2] F. Saad,et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. , 2022, The New England journal of medicine.
[3] C. Porta,et al. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. , 2021, European Journal of Cancer.
[4] M. Climent,et al. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020) , 2021, Clinical and Translational Oncology.
[5] C. Parker,et al. Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] S. Egawa,et al. Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy , 2019, The world journal of men's health.
[7] M. Stockler,et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.
[8] M. Borre,et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.
[10] F. Saad,et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 , 2016, European urology.
[11] D. Petrylak,et al. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.
[12] J. Burke,et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. , 2015, The Lancet. Oncology.
[13] E. Antonarakis,et al. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Giannakakou,et al. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. , 2012, Cancer research.
[15] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.